Star Metro - Zomedica Announces Launch of the Assisi Loop Lounge(R), Scientifically Backed tPEMF(TM) Therapy for Pets

ANN ARBOR, MI / ACCESS Newswire / October 23, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the launch of the Assisi Loop Lounge, a next-generation targeted pulsed electromagnetic field (tPEMF) therapy bed delivering full-body treatment and luxurious comfort for pets, now featuring unlimited uses and a lifetime warranty to provide lasting therapeutic value for pet owners and veterinary professionals alike.

The Assisi Loop Lounge is the only small animal tPEMF device backed by peer-reviewed scientific research, making it the trusted choice of veterinarians and pet owners worldwide. Recognized globally as the leader in evidence-based tPEMF therapy, the Assisi brand continues to redefine non-invasive healing for companion animals through scientifically validated technology and exceptional user experience.

"Not all tPEMF devices are created equal," said Nicole Westfall, Senior Vice President of Marketing at Zomedica. "The Assisi Loop Lounge combines scientifically proven tPEMF technology preferred, trusted, and recommended in veterinary medicine with a beautifully designed, comfortable solution that pet owners feel good about bringing into their homes. It's truly where science meets love™."

Versatile Healing-From Clinics to Homes and Beyond

The Assisi Loop Lounge is used by veterinary clinics to relieve pain and inflammation during treatment and recovery. In hospice and palliative care, it provides gentle comfort for pets nearing the end of life. At home, pet parents use the Lounge daily for the management of osteoarthritis, chronic pain, post-surgical recovery, and overall mobility support.

Its lightweight, portable design makes it ideal for long car rides and travel, fitting easily into most pet carriers to provide therapeutic comfort on the go. Available in multiple sizes, the Lounge is suitable for dogs, cats, rabbits, and even exotic animals, offering a compassionate solution for a wide range of species and needs.

Unlimited Treatments, Lifetime Warranty

With unlimited treatments and a lifetime warranty, the Loop Lounge delivers unmatched long-term reliability and peace of mind. This ensures continuous therapeutic support throughout a pet's lifetime, reinforcing Zomedica's commitment to quality, durability, and animal wellness.

Constructed with three inches of premium orthopedic foam, a liquid-resistant liner, and a performance fabric cover, the Lounge provides an ideal blend of comfort and functionality for pets recovering from injury, living with chronic conditions, or simply aging gracefully.

Mialisa Gluckert, Senior Director of Commercialization at Zomedica, added, "The Loop Lounge reinforces our leadership in therapeutic innovation. As the only scientifically backed tPEMF device in the small animal market, Assisi continues to set the benchmark for evidence-based healing. Veterinarians choose it for its proven efficacy; pet owners choose it because they see the difference in their animals' comfort, recovery, and quality of life."

Trusted by Rehabilitation Experts

"As a rehabilitation veterinarian, the Assisi Loop Lounge is a critical component of my practice," said Dr. Matthew Brunke, DVM, DACVSMR (Canine), CCAT, Fellow, IAVRPT. "It provides consistent, evidence-based pain relief and accelerates recovery for my patients. Whether in the clinic or at home, it gives veterinarians and owners a safe, effective tool to improve quality of life and support long-term healing."

Expanding Market Opportunity

The global animal-health tPEMF and electrotherapy market is valued at approximately $400-500 million in 2025 and projected to grow at a compound annual rate of 8-10% through 2031, driven by increasing pet ownership, a growing preference for non-pharmaceutical pain management, and wider adoption of rehabilitation technologies (source: Global Veterinary Rehabilitation Devices Report, 2025).

Assisi products are supported by more than a decade of peer-reviewed research demonstrating the clinical benefits of targeted pulsed electromagnetic field therapy in reducing inflammation, accelerating healing, and improving mobility in companion animals. The Assisi Loop Lounge reflects Zomedica's dedication to delivering technologies "where science meets love."

Learn more about the Assisi Loop Lounge at www.assisianimalhealth.com and get yours today. Now available through veterinarians, select online retailers, and directly from Zomedica.

About Zomedica

Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet^® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi Loop^® line of therapeutic devices, the TRUFORMA^® diagnostic platform, the TRUVIEW^® digital cytology system, the VETGuardian^® no-touch monitoring system, and VETIGEL^® hemostatic gel, a revolutionary hemostatic gel that rapidly stops bleeding-each designed to empower veterinarians to deliver top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 8% in 2024 to $27 million and maintains a strong balance sheet with approximately $59 million in liquidity as of June 30, 2025. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.

Follow Zomedica

• Email Alerts: http://investors.zomedica.com

• LinkedIn: https://www.linkedin.com/company/zomedica

• Facebook: https://m.facebook.com/zomedica

• X (formerly Twitter): https://twitter.com/zomedica

• Instagram: https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward-Looking Statements

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment, particularly in Europe; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:
Zomedica Investor Relations
[email protected]
1-734-369-2555

SOURCE: Zomedica Corp.

View the original press release on ACCESS Newswire

O.Martin--SMC